• Home
  • Project
  • Partners
    • Advisory board
    • Investigators
    • Institutes
      • LUMC
      • Inserm
      • UCL
      • Great Ormond Street
      • Ospedale San Raffaele
      • Hannover Medical School
      • University of Ulm
      • Wroclaw University
      • Newcastle University
      • IPOPI
      • Batavia Biosciences
      • Vall d’Hebron Hospital
      • Bambino Gesù
      • SCETIDE
      • Sheba Medical Center
      • LMU
      • GeneWerk
    • Partner area
  • Impact
  • Resources
    • Leaflet
    • Videos
  • Contact
  • News

Slide RECOMB Clinical trial for RAG1-SCID
home_science_icon5

Develop

Develop an autologous haematopoietic stem cell‒based gene therapy within a multinational, multicentre clinical trial for treating RAG1-SCID.
home_science_icon4

Treat

Treat the patients with the developed RAG1-SCID gene therapy eliminating complications and increasing survival.
home_science_icon1

Impact

Make gene therapy a realistic option for > 70% of all SCID patients in Europe with reduced healthcare costs.
parallax background

News


Read more
June 22, 2022

First patient in the Netherlands successfully treated with stem cell gene therapy

Do you like it?18
0 Read more
May 30, 2022

Article over the progress of the Recomb project

Do you like it?18
0 Read more

About us

The RECOMB consortium brings together a large number of clinical and research professionals from 16 European and 1 Israeli institutes with expertise in the management of primary immunodeficiencies, such as SCID.

Our mission

The ultimate aim of RECOMB is to create a treatment for the most common type of SCID, RAG1-SCID by performing phase 1 and phase 2 clinical trials using autologous haematopoietic stem cell‒based gene therapy.

Useful links

  • Learn more about Primary immunodeficiencies
  • Learn more about SCID
  • Learn more about Gene Therapy

This project has received funding from the  European Union’s Horizon 2020 research and 
innovation programme under grant agreement n° 755170’

© 2022 RECOMB. All Rights Reserved. Muffin group